Artificial Intelligence to Guide Precision Anticancer Therapy with Multitargeted Kinase Inhibitors

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Nov 26

PMID 36434556

Authors

Manali Singha

Limeng Pu

Brent A Stanfield

Ifeanyi K Uche

Paul J F Rider

Konstantin G Kousoulas

J Ramanujam

Michal Brylinski

Affiliations

Soon will be listed here.

Abstract

Background: Vast amounts of rapidly accumulating biological data related to cancer and a remarkable progress in the field of artificial intelligence (AI) have paved the way for precision oncology. Our recent contribution to this area of research is CancerOmicsNet, an AI-based system to predict the therapeutic effects of multitargeted kinase inhibitors across various cancers. This approach was previously demonstrated to outperform other deep learning methods, graph kernel models, molecular docking, and drug binding pocket matching.

Methods: CancerOmicsNet integrates multiple heterogeneous data by utilizing a deep graph learning model with sophisticated attention propagation mechanisms to extract highly predictive features from cancer-specific networks. The AI-based system was devised to provide more accurate and robust predictions than data-driven therapeutic discovery using gene signature reversion.

Results: Selected CancerOmicsNet predictions obtained for "unseen" data are positively validated against the biomedical literature and by live-cell time course inhibition assays performed against breast, pancreatic, and prostate cancer cell lines. Encouragingly, six molecules exhibited dose-dependent antiproliferative activities, with pan-CDK inhibitor JNJ-7706621 and Src inhibitor PP1 being the most potent against the pancreatic cancer cell line Panc 04.03.

Conclusions: CancerOmicsNet is a promising AI-based platform to help guide the development of new approaches in precision oncology involving a variety of tumor types and therapeutics.

Citing Articles

Cheminformatic Identification of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors: A Comparative Study of SMILES-Based Supervised Machine Learning Models.

Lai C, Kwok A, Wong K J Pers Med. 2024; 14(9).

PMID: 39338235 PMC: 11433629. DOI: 10.3390/jpm14090981.

Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research.

Witt B, Tollefsbol T Life (Basel). 2023; 13(12).

PMID: 38137912 PMC: 10744609. DOI: 10.3390/life13122311.

Graph Neural Networks in Cancer and Oncology Research: Emerging and Future Trends.

Gogoshin G, Rodin A Cancers (Basel). 2023; 15(24).

PMID: 38136405 PMC: 10742144. DOI: 10.3390/cancers15245858.

Opportunities and challenges of 5G network technology toward precision medicine.

Kang C, Lee T, Lim W, Yeo W Clin Transl Sci. 2023; 16(11):2078-2094.

PMID: 37702288 PMC: 10651640. DOI: 10.1111/cts.13640.

Unlocking the Potential of Kinase Targets in Cancer: Insights from CancerOmicsNet, an AI-Driven Approach to Drug Response Prediction in Cancer.

Singha M, Pu L, Srivastava G, Ni X, Stanfield B, Uche I Cancers (Basel). 2023; 15(16).

PMID: 37627077 PMC: 10452340. DOI: 10.3390/cancers15164050.

References

Sorgenfrei F, Fulle S, Merget B . Kinome-Wide Profiling Prediction of Small Molecules. ChemMedChem. 2017; 13(6):495-499. DOI: 10.1002/cmdc.201700180. View

Lo K, Stein L, Panzarella J, Cowell J, Hawthorn L . Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis. Lung Cancer. 2007; 59(3):315-31. DOI: 10.1016/j.lungcan.2007.08.037. View

Ma X, Lv X, Zhang J . Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. Eur J Med Chem. 2017; 143:449-463. DOI: 10.1016/j.ejmech.2017.11.049. View

Brylinski M, Skolnick J . Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening. J Chem Inf Model. 2010; 50(10):1839-54. PMC: 2963673. DOI: 10.1021/ci100235n. View

Ricciarelli R, dAbramo C, Massone S, Marinari U, Pronzato M, Tabaton M . Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life. 2004; 56(6):349-54. DOI: 10.1080/15216540412331286002. View

Jo T, Nho K, Bice P, Saykin A . Deep learning-based identification of genetic variants: application to Alzheimer's disease classification. Brief Bioinform. 2022; 23(2). PMC: 8921609. DOI: 10.1093/bib/bbac022. View

Liu R, Wei L, Zhang P . A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. Nat Mach Intell. 2022; 3(1):68-75. PMC: 9119409. DOI: 10.1038/s42256-020-00276-w. View

Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, Settleman J . Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med Chem Lett. 2011; 2(3):195-200. PMC: 3055678. DOI: 10.1021/ml100304b. View

Chan J, Wang X, Turner J, Baldwin N, Gu J . Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. 2019; 35(16):2818-2826. PMC: 6691331. DOI: 10.1093/bioinformatics/btz006. View

10.

Pletscher-Frankild S, Palleja A, Tsafou K, Binder J, Jensen L . DISEASES: text mining and data integration of disease-gene associations. Methods. 2014; 74:83-9. DOI: 10.1016/j.ymeth.2014.11.020. View

11.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

12.

Tatton L, Morley G, Chopra R, Khwaja A . The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem. 2002; 278(7):4847-53. DOI: 10.1074/jbc.M209321200. View

13.

Shi W, Lemoine J, Shawky A, Singha M, Pu L, Yang S . BionoiNet: ligand-binding site classification with off-the-shelf deep neural network. Bioinformatics. 2020; 36(10):3077-3083. PMC: 7214032. DOI: 10.1093/bioinformatics/btaa094. View

14.

Coxon A, Ziegler B, Kaufman S, Xu M, Wang H, Weishuhn D . Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012; 11:70. PMC: 3515409. DOI: 10.1186/1476-4598-11-70. View

15.

Nylander S, Kull B, Bjorkman J, Ulvinge J, Oakes N, Emanuelsson B . Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012; 10(10):2127-36. DOI: 10.1111/j.1538-7836.2012.04898.x. View

16.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

17.

Zhao H, Yang F, Huang X, Zhou Q . Overview of fundamental study of pazopanib in cancer. Thorac Cancer. 2016; 5(6):487-93. PMC: 4704340. DOI: 10.1111/1759-7714.12136. View

18.

Vigushin D, Ali S, Pace P, Mirsaidi N, Ito K, Adcock I . Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001; 7(4):971-6. View

19.

Shabbir M, Stuart R . Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010; 19(3):427-36. DOI: 10.1517/13543781003598862. View

20.

Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam R . Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006; 10(4):331-42. DOI: 10.1016/j.ccr.2006.09.006. View